Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Director | June 14, 2019 | June 18, 2019 |
| Parabilis Medicines, Inc.PBLS · Entity 3933 | Director | June 09, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date June 14, 2019 · Filed June 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.74 · Expires 2029-06-13 | Direct | 26,400 |
Reported balance
After 2019-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-14 · Grant · Acquired 26,400 · Balance 26,400 F1: The shares vest over a four year period in equal annual installments beginning on June 14, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest over a four year period in equal annual installments beginning on June 14, 2019.
Parabilis Medicines, Inc.
Report date June 09, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,688 |
Ending reported balance
After 2026-06-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-11 · Conversion · Acquired 5,539 · Balance 5,539 F1: Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date. Row 2 · 2026-06-11 · Conversion · Acquired 3,878 · Balance 9,417 F2: Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date. Row 3 · 2026-06-11 · Conversion · Acquired 5,271 · Balance 14,688 F3: Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Conversion · Acquired 5,332 · Balance 0 F1: Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-11 · Conversion · Acquired 3,666 · Balance 0 F2: Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date. |
| Series F Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-11 · Conversion · Acquired 8,111 · Balance 0 F3: Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date.
F2: Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date.
F3: Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:35 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionSeries F Preferred Stock · Derivative | 8,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-271344 · ownership.xml · derivative · entry 6 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date. F3 · price: Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date. F3 · derivative.exercise_date: Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date. F3 · derivative.expiration_date: Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:35 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionSeries C Preferred Stock · Derivative | 3,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-271344 · ownership.xml · derivative · entry 5 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date. F2 · price: Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:35 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionSeries B Preferred Stock · Derivative | 5,332 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-271344 · ownership.xml · derivative · entry 4 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,539 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date. F1 · price: Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:35 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionCommon Stock | 5,271 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-271344 · ownership.xml · nonDerivative · entry 3 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:35 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionCommon Stock | 3,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-271344 · ownership.xml · nonDerivative · entry 2 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:35 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | ConversionCommon Stock | 5,539 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-271344 · ownership.xml · nonDerivative · entry 1 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:48 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | GrantStock Option (Right to Buy) · Derivative | 20,215 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001193125-26-267769 · ownership.xml · derivative · entry 1 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,215 Underlying: Common Stock · 20,215 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 20:31 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 26,400 | $0.00 Strike: $22.74 | $0.00 |
DisclosureSEC source: 0001209191-19-037700 · doc4.xml · derivative · entry 1 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares vest over a four year period in equal annual installments beginning on June 14, 2019. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:06 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 26,400 | $0.00 Strike: $23.46 | $0.00 |
DisclosureSEC source: 0001209191-18-035591 · doc4.xml · derivative · entry 1 FITZGERALD EDWARD M · CIK 0001242993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2028-05-31 F1 · derivative.exercise_date: The shares vest over a four year period in equal annual installments beginning on June 1, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.